positions available now

Tag Archives: Health Technology

What is food for special medical purposes (FSMP)?

With a greater recognition of the importance of nutritional support in medical therapy and improved technology, the “food for special medical purposes” (FSMP) market is currently surging. However, many questions arise, what is food for special medical purposes? Where can … Continue reading

Posted in Life Sciences Industry, Medical Services, TGA | Tagged , , , | Comments Off on What is food for special medical purposes (FSMP)?

Multi-criteria decision making – How can non-health attributes be considered and valued?

Pressure is mounting on decisions to recommend and continue funding health technologies. Concerns around the rising cost of new medicines, an ageing population with greater resource utilisation, federal and state healthcare budgetary constraints, and an increasing dependency ratio (the ratio … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged | Comments Off on Multi-criteria decision making – How can non-health attributes be considered and valued?

Successful innovation has economic and social benefits such as creating jobs and improving the quality of lives

With the launch of Malcolm Turnbull’s Innovation statement and Innovation Week 2015 in Victoria last week, the hot topic of discussion is ‘innovation’. Here’s what Andrew Carter, Commercial Eyes Managing Director and Chair of BioMelbourne Network, has to say… Policies that … Continue reading

Posted in BioMelbourne Network, Commercial Eyes, Life Sciences Industry | Tagged , | Comments Off on Successful innovation has economic and social benefits such as creating jobs and improving the quality of lives

Medical Information by instant message

1800 numbers and written responses such as letters and emails are a well-established part of all Medical Information services. However consumers and healthcare professionals are increasingly tech-savvy. They may prefer to communicate via text or online chat as they do … Continue reading

Posted in E-Health/Technology, Medical Services | Tagged , , | Comments Off on Medical Information by instant message

NZ Regs Shake-up – what will become of medical devices?

The New Zealand Ministry of Health has announced that they are developing a new regime for the regulation of therapeutic products. Following the cessation of the Australia New Zealand Therapeutic Products Agency (ANZTPA), the New Zealand Ministry of Health is … Continue reading

Posted in Life Sciences Industry, Medical Device, Regulatory Services | Tagged , , , , | Comments Off on NZ Regs Shake-up – what will become of medical devices?

Launch sequencing and the 5% F1 price cut: strategic considerations for your patented medicine

Achieving optimal prices for patented medicines is a critical issue close to the heart of the pharmaceutical industry. The 2015/16 Federal Budget introduced new savings measures with implications for prices of patented medicines in Australia. In the current environment, launch … Continue reading

Posted in Federal Budget, Life Sciences Industry, Market Access | Tagged | Comments Off on Launch sequencing and the 5% F1 price cut: strategic considerations for your patented medicine

Funding pathways for new technologies

Recently, the topic of funding pathways for new technologies was discussed as part of a speaker session at the 2015 ARCS Scientific Congress, at Royal Randwick Sydney. Professor Robyn Ward, the current Chairperson of MSAC and a member of the … Continue reading

Posted in Life Sciences Industry, Market Access, MSAC | Tagged , | Comments Off on Funding pathways for new technologies

2014 ARCS scientific congress: ethics in HTA and decision-making

Posted in Life Sciences Industry, Market Access | Tagged , , | Comments Off on 2014 ARCS scientific congress: ethics in HTA and decision-making

clinical trial design – overcoming the odds

Drug development costs anywhere between $1-4 billion by the time costs of failed drug candidates are factored in. A new drug can take anywhere from 10-15 years to obtain approval for human use. 80-85% of compounds fail early phase clinical … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access | Tagged , , | Comments Off on clinical trial design – overcoming the odds

Disinvestment in health care: friend or foe?

The clinical trial that led Commercial Eyes Market Access Consultant, Bridie Murphy, into the world of health technology assessment is still in the spotlight five years on. In July, The Conversation featured an article that looked at this and other … Continue reading

Posted in Clinical Development, Commercial Eyes, Life Sciences Industry, Market Access, MSAC | Tagged , , , | Comments Off on Disinvestment in health care: friend or foe?
Copyright © 2014 Commercial Eyes